| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-64895SS | |||
| Azide and BSA Free | NBP2-80651 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-48337SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-724SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-48338SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| IHC-Prediluted | NBP2-44857 | |||
| Azide and BSA Free | NBP2-34528-1mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-80289-20ul | |||
![Flow Cytometry: CD45 Antibody (OX-1) [NB100-64895] - Analysis using Alexa Fluor (R) 488 conjugate of CD45 antibody (OX-1). Rat Splenocytes were stained with CD45 antibody (OX-1) [NB100-64895] (blue) and a matched isotype control [NBP2-27287] (orange). Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/CD45-Antibody-OX-1-Flow-Cytometry-NB100-64895-img0005.jpg "Flow Cytometry: CD45 Antibody (OX-1) [NB100-64895] - Analysis using Alexa Fluor (R) 488 conjugate of CD45 antibody (OX-1). Rat Splenocytes were stained with CD45 antibody (OX-1) [NB100-64895] (blue) and a matched isotype control [NBP2-27287] (orange). Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.")
![Flow Cytometry: CD45 Antibody (OX-1) [NB100-64895] - Analysis using the FITC conjugate of CD45 antibody (OX-1). Staining of rat spleen cells.](http://images.novusbio.com/fullsize/CD45-Antibody-OX-1-Flow-Cytometry-NB100-64895-img0004.jpg)
![Flow Cytometry: CD45 Antibody (OX-1) - BSA Free [NB100-64895] - Representative sequential gating during flow cytometry analysis of rat non-parenchymal liver cells (n = 4). Cells were labeled with antibodies to SE-1 (NB110-68095AF488), CD31, and CD45 (NB100-64895PE). LSECs were then identified as SE-1-Alexa488+ cells (e), and the biexponential CD45-PE/CD31-APC of events (f) were used to display and select the CD45+ CD31+ subsets of LSECs. FMOs (used for gating), and single antibody staining controls are shown in Additional file. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33246411/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD45-Antibody-OX-1-BSA-Free-Flow-Cytometry-NB100-64895-img0006.jpg)
![Flow Cytometry: CD45 Antibody (OX-1) [NB100-64895] - Staining of rat peripheral blood lymphocytes with mouse anti-rat CD45 antibody (OX-1) [NB100-64895].](http://images.novusbio.com/fullsize/CD45-Antibody-OX-1-Flow-Cytometry-NB100-64895-img0001.jpg)
![Western Blot: nNOS Antibody [NBP1-39681] - Effects of ER alpha and ER beta Antagonists on NE Regulation of VMN nNOS Protein Expression. Micropunch-dissected VMN tissue was obtained from groups of ovariectomized, estradiol-replaced female rats pretreated by intra-VMN delivery of MPP, PHTPP, or vehicle (Veh) prior to NE administration for Western blot analysis of neuronal nitric oxide synthase (nNOS) - Panel 2A,F(5, 12)=12.67,p<.0001 - protein expression. Data depict mean normalized protein optical density (O.D.) values+/-SEMfor groups of rats (n=6 per group) infused with Veh (white bars) or NE (gray bars) after delivery of Veh (solid bars), MPP (diagonal-striped bars), or PHTPP (cross-hatched bars) administration. *p<.05; **p<.01; ***p<.001. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32233668/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/nNOS-Antibody-Western-Blot-NBP1-39681-img0007.jpg "Western Blot: nNOS Antibody [NBP1-39681] - Effects of ER alpha and ER beta Antagonists on NE Regulation of VMN nNOS Protein Expression. Micropunch-dissected VMN tissue was obtained from groups of ovariectomized, estradiol-replaced female rats pretreated by intra-VMN delivery of MPP, PHTPP, or vehicle (Veh) prior to NE administration for Western blot analysis of neuronal nitric oxide synthase (nNOS) - Panel 2A,F(5, 12)=12.67,p<.0001 - protein expression. Data depict mean normalized protein optical density (O.D.) values+/-SEMfor groups of rats (n=6 per group) infused with Veh (white bars) or NE (gray bars) after delivery of Veh (solid bars), MPP (diagonal-striped bars), or PHTPP (cross-hatched bars) administration. *p<.05; **p<.01; ***p<.001. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32233668/) licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: nNOS Antibody [NBP1-39681] - Analysis of anti-nNOS / NOS1 antibody with human brain, cerebellum at concentration 5 ug/ml.](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunohistochemistry-Paraffin-NBP1-39681-img0004.jpg)
![Western Blot: nNOS Antibody [NBP1-39681]](http://images.novusbio.com/fullsize/nNOS-Antibody-Western-Blot-NBP1-39681-img0006.jpg)
![Immunohistochemistry-Paraffin: nNOS Antibody [NBP1-39681] - Analysis of anti-nNOS / NOS1 antibody with human brain, cortex at concentration 5 ug/ml.](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunohistochemistry-Paraffin-NBP1-39681-img0003.jpg)
![Western Blot: nNOS Antibody [NBP1-39681] - Laser-Catapult Microdissection of Immunolabeled ventromedial hypothalamic nucleus (VMN) GABA or Nitrergic Neurons: Western Blot Confirmation of Accuracy of Immunocytochemical Identification of Neurotransmitter Phenotype. VMN neurons were identified in situ for glutamate decarboxylase65/67 (GAD65/67)- (top row, Panel 1A) or neuronal nitric oxide (nNOS)-immunoreactivity (-ir) (bottom row, Panel 2A); representative GAD65/67- or nNOS-ir-positive neurons are indicated by blue arrows. Areas shown in Panels 1A & 2A were rephotographed after positioning of a continuous laser track (depicted in green) around a single GAD65/67-ir (Panel 1B, blue arrow) or nNOS-ir neuron (Panel 2B, blue arrow) & subsequent ejection of the encircled cell by laser pulse (Panels 1C & 2C). Note that this microdissection technique causes negligible destruction of surrounding tissue & minimal inclusion of adjacent tissue. Western blot analysis of triplicate cell lysate pools produced from immunolabeled GAD65/67 (Panel 1D) or nNOS (Panel 2D) neurons from Veh/Veh animals showed that these proteins are expressed in VMN neuron samples obtained by combinatory immunocytochemistry/laser-catapult microdissection. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32233668), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-39681_rabbit-nnos-pab-310202416154636.jpg)
![Western Blot: nNOS Antibody [NBP1-39681] - Effects of ER alpha & ER beta Antagonists on NE Regulation of VMN GAD & nNOS Protein Expression. Micropunch-dissected VMN tissue was obtained from groups of ovariectomized, estradiol-replaced female rats pretreated by intra-VMN delivery of MPP, PHTPP, or vehicle (Veh) prior to NE administration for Western blot analysis of neuronal nitric oxide synthase (nNOS)—Panel 2A, F(5, 12) = 12.67, p < .0001—or glutamate decarboxylase65/67 (GAD)—Panel 2B, F(5, 12) = 7.13, p = .0003—protein expression. Data depict mean normalized protein optical density (O.D.) values ± SEM for groups of rats (n = 6 per group) infused with Veh (white bars) or NE (gray bars) after delivery of Veh (solid bars), MPP (diagonal-striped bars), or PHTPP (cross-hatched bars) administration. *p < .05; **p < .01; ***p < .001. MPP = 1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride; PHTPP = 4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol; NE = norepinephrine. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32233668), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-39681_rabbit-nnos-pab-310202416175279.jpg)
![Immunohistochemistry: CCR2 Antibody [NBP1-48337] - Localization of CCR1 (binds to CCL8, CCL14, and CCL16), CCR2 (binds to CCL2, CCL8, and CCL16), CCR3 (binds to CCL11), and CXCR3 (binds to CXCL10) in the bovine endometrium and fetal trophoblast obtained from cows in their 18th day of pregnancy. Intensive immunoreactivity was observed in endometrial epithelial cells, glandular epithelial cells, or fetal trophoblast. No positive immunoreactivity was observed in the negative control (Control). Scale bar = 50 um. Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/1422-0067/18/4/742), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-NBP1-48337-img0017.jpg "Immunohistochemistry: CCR2 Antibody [NBP1-48337] - Localization of CCR1 (binds to CCL8, CCL14, and CCL16), CCR2 (binds to CCL2, CCL8, and CCL16), CCR3 (binds to CCL11), and CXCR3 (binds to CXCL10) in the bovine endometrium and fetal trophoblast obtained from cows in their 18th day of pregnancy. Intensive immunoreactivity was observed in endometrial epithelial cells, glandular epithelial cells, or fetal trophoblast. No positive immunoreactivity was observed in the negative control (Control). Scale bar = 50 um. Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/1422-0067/18/4/742), licensed under a CC-BY license.")
![Western Blot: CCR2 Antibody [NBP1-48337] - Analysis of CCR2 in rat lysate. Image courtesy of product review submitted by Rasha Elbaz.](http://images.novusbio.com/fullsize/CCR2-Antibody-Western-Blot-NBP1-48337-img0005.jpg)
![Flow Cytometry: CCR2 Antibody - BSA Free [NBP1-48337] - An intracellular stain was performed on U2-OS cells with CCR2 NBP1-48337AF647 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/CCR2-Antibody---BSA-Free-Flow-Cytometry-NBP1-48337-img0020.jpg)
![Immunohistochemistry-Paraffin: CCR2 Antibody [NBP1-48337] - Analysis of FFPE tissue section of human liver cancer using 5 ug/ml concentration of CCR2 antibody. Intense cytoplasmic-membranous immune-staining was observed in the cancerous hepatocytes, whereas the staining was relatively weak in the cells adjacent to the fibrotic areas. [Magnification 40X]](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-Paraffin-NBP1-48337-img0011.jpg)
![Immunohistochemistry-Paraffin: CCR2 Antibody [NBP1-48337] - Analysis of FFPE tissue section of human rectal adenocarcinoma using 5 ug/ml concentration of CCR2 antibody. The cancerous cells in the section developed a uniform but specific CCR2 immunopositivity whereas a weak staining was seen in the tumor stroma cells. [Magnification 40X]](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-Paraffin-NBP1-48337-img0012.jpg)
![Immunohistochemistry-Paraffin: CCR2 Antibody [NBP1-48337] - Analysis of FFPE section of human esophageal squamous cell carcinoma (SCC) using 5 ug/ml concentration of CCR2 antibody. Strong cytoplasmic-membranous immune-staining was observed in SCC cells and a relatively weaker staining was seen in the tumor stroma cells. [Magnification 10X]](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-Paraffin-NBP1-48337-img0013.jpg)
![Immunohistochemistry-Paraffin: CCR2 Antibody [NBP1-48337] - Analysis of FFPE tissue section of human normal kidney using 5 ug/ml concentration of CCR2 antibody. Strong cytoplasmic immunostaining was observed in the various renal cells (especially from tubules/ducts epithelium). The cells of Bowman's capsule depicted a very weak cytoplasmic staining for CCR2 protein. [Magnification 10X]](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-Paraffin-NBP1-48337-img0014.jpg)
![Immunohistochemistry-Paraffin: CCR2 Antibody [NBP1-48337] - Analysis of FFPE tissue section of human normal breast using 5 ug/ml concentration of CCR2 antibody. The breast ductal/acinar epithelial cells showed a strong cytoplasmic-membranous CCR2 immune-positivity, whereas the intra-lobular connective tissue depicted weak staining. [Magnification 40X]](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-Paraffin-NBP1-48337-img0015.jpg)
![Flow Cytometry: CCR2 Antibody [NBP1-48337] - An intracellular stain was performed on THP-1 cells with CCR Antibody NBP1-48337R (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 550.](http://images.novusbio.com/fullsize/CCR2-Antibody-Flow-Cytometry-NBP1-48337-img0016.jpg)
![Flow Cytometry: CCR2 Antibody [NBP1-48337] - An intracellular stain was performed on THP-1 cells with CCR2 Antibody NBP1-48337 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/CCR2-Antibody-Flow-Cytometry-NBP1-48337-img0018.jpg)
![Flow Cytometry: CCR2 Antibody - BSA Free [NBP1-48337] - An intracellular stain was performed on U2-OS cells with CCR2 NBP1-48337 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/CCR2-Antibody---BSA-Free-Flow-Cytometry-NBP1-48337-img0019.jpg)
![Immunocytochemistry/Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - CTGF antibody was tested in U2OS cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/CTGF-CCN2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-724-img0004.jpg "Immunocytochemistry/Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - CTGF antibody was tested in U2OS cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).")
![Immunohistochemistry-Paraffin: CTGF/CCN2 Antibody [NB100-724] - Analysis of a FFPE tissue section of human lymph node using 1:200 dilution of CTGF/CCN2 antibody (NB100-724). The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/CTGF-CCN2-Antibody-Immunohistochemistry-Paraffin-NB100-724-img0005.jpg)
![Immunocytochemistry/ Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - Analysis of astrocyte reactivity, the cytoskeleton & migration rate following treatment with TGF-beta 2 & CCN2/CTGF. (A) GFAP immunoreactivity (green) is increased in murine ON astrocytes following TGF-beta 2 & CCN2/CTGF treatment. Nuclei are stained with Dapi (blue) (B) Western Blot experiments analyses of alpha -actinin protein synthesis in murine ON astrocytes after the treatment with 1 ng/ml TGF-beta 2, 50 ng/ml CCN2/CTGF & 100 ng/ml CCN2/CTGF for 24 h. Densitometric analyses of Western Blot analyses shows the significant increase in alpha -actinin protein synthesis. Mean value of untreated cells (control) was set at 1. GAPDH was used to normalize protein intensity (n = 4; 50 ng CCN2/CTGF: *p = 0.029; 100 ng CCN2/CTGF: *p = 0.015; unpaired two-tailed t-test). (C) Scratch assay analyses show a significant increased migration rate for murine ON astrocytes after the treatment with ng/ml TGF-beta 2, 50 ng/ml CCN2/CTGF & 100 ng/ml CCN2/CTGF for 12 h. Mean value of migration rate of control cells was set to 100% (control: n = 15; TGF-beta 2: n = 12, **p = 0.008; 50 ng/ml CCN2/CTGF: n = 10, *p = 0.001; 100 ng/ml CCN2/CTGF: n = 4, **p = 0.0001). Data represented as mean ± SD. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-31020241683912.jpg)
![Immunohistochemistry: CTGF/CCN2 Antibody [NB100-724] - GFAP expression & synthesis in the ON & ONH in a murine glaucoma model. (A) GFAP immunoreactivity in the glial lamina of 1-month (green, upper panel) & 2 months (green, middle & lower panel) old beta B1-CTGF1 mice compared to WT controls. Immunoreactivity of GFAP not altered in 1-month old TG & WT animals (green, upper panel). 2 month old beta B1-CTGF1 mice showed an increased GFAP immunoreactivity compared to WT control (green, middle panel). Lower panel shows a magnified detail of the middle panel. Nuclei are stained w/ Dapi (blue). (B) Schmatic illustration of the optic nerve. A depicts region in the glial lamina where cross sections obtained. ONH (unmyelinated part) & ON (myelinated part) used for molecular analysis. (C) Quantification of immunohistochemical staining of GFAP in the glial lamina is not altered in 1 month old TG & WT animals (WT: n = 5; TG: n = 4). GFAP immunoreactivity is increased in 2 month old TG animals compared to WT littermates (WT: n = 10, TG: n = 13; *p = 0.039; two-tailed t-test compared to oretical mean of 1 (normalized control)). Mean value of WT animals (control) set at 1. (D) RT-PCR analyses revealed no alteration in the Gfap mRNA expression in the ON of 1-month (WT: n = 7; TG: n = 5) & 2 month old beta B1-CTGF1 mice (WT: n = 15; TG: n = 16) compared to WT controls. In the ONH the Gfap mRNA expression is increased in the 2 month old TG compared to WT animals (WT: n = 6, TG: n = 5; *p = 0.04). The mRNA expression of Gfap is not altered in 1 month old animals (WT: n = 6, TG: n = 5). Mean value of WT animals (control) set at 1. RPL32 used to normalize mRNA expression. Data represented as mean ± SEM. PRL, Prelaminar region; PSL, Postlaminar region; ON, optic nerve; ONH, optic nerve head. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-310202415523931.jpg)
![Immunohistochemistry: CTGF/CCN2 Antibody [NB100-724] - GFAP expression & synthesis in the ON & ONH in a murine glaucoma model. (A) GFAP immunoreactivity in the glial lamina of 1-month (green, upper panel) & 2 months (green, middle & lower panel) old beta B1-CTGF1 mice compared to WT controls. Immunoreactivity of GFAP not altered in 1-month old TG & WT animals (green, upper panel). 2 month old beta B1-CTGF1 mice showed an increased GFAP immunoreactivity compared to WT control (green, middle panel). Lower panel shows a magnified detail of the middle panel. Nuclei are stained w/ Dapi (blue). (B) Schmatic illustration of the optic nerve. A depicts region in the glial lamina where cross sections obtained. ONH (unmyelinated part) & ON (myelinated part) used for molecular analysis. (C) Quantification of immunohistochemical staining of GFAP in the glial lamina is not altered in 1 month old TG & WT animals (WT: n = 5; TG: n = 4). GFAP immunoreactivity is increased in 2 month old TG animals compared to WT littermates (WT: n = 10, TG: n = 13; *p = 0.039; two-tailed t-test compared to oretical mean of 1 (normalized control)). Mean value of WT animals (control) set at 1. (D) RT-PCR analyses revealed no alteration in the Gfap mRNA expression in the ON of 1-month (WT: n = 7; TG: n = 5) & 2 month old beta B1-CTGF1 mice (WT: n = 15; TG: n = 16) compared to WT controls. In the ONH the Gfap mRNA expression is increased in the 2 month old TG compared to WT animals (WT: n = 6, TG: n = 5; *p = 0.04). The mRNA expression of Gfap is not altered in 1 month old animals (WT: n = 6, TG: n = 5). Mean value of WT animals (control) set at 1. RPL32 used to normalize mRNA expression. Data represented as mean ± SEM. PRL, Prelaminar region; PSL, Postlaminar region; ON, optic nerve; ONH, optic nerve head. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-310202415535150.jpg)
![Immunocytochemistry/ Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - Analyses of ECM components in murine ON astrocytes following treatment w/ TGF-beta 2 & CCN2/CTGF. (A) Immunocytochemical staining against fibronectin (green, upper panel) showed a markedly increase following the treatment w/ 1 ng/ml TGF-beta 2 or 50 ng/ml CCN2/CTGF. Immunocytochemical staining against tropoelastin (green, lower panel) showed a pronounced increase after treatment w/ 1 ng/ml TGF-beta 2 or 50 ng/ml CCN2/CTGF. Nuclei stained w/ Dapi (blue). (B) Real-time RT-PCR analyses shows an intense upregulation of collagen 3 alpha 1, tropoelastin & fibronectin mRNA in murine ON astrocytes after treatment w/ 1 ng/ml TGF-beta 2, 50 ng/ml CCN2/CTGF or 100 ng/ml CCN2/CTGF for 24 h compared to untreated control cells (collagen 3 alpha 1: n = 3; TGF-beta 2 ***p = 0.0000004, 50 ngCTGF **p = 0.005, 100ngCTGF **p = 0.008; fibronectin: n = 6, TGF-beta 2 *p = 0.00004, 50 ng CTGF *p = 0.016, 100 ngCTGF *p = 0.05; elastin: n = 5, TGF-beta 2 *p = 0.026, 50 ng CTGF *0.04, 100 ng CTGF *p = 0.03). mRNA expression normalized to Gnb2l & mean value of control cells set at 1. (C) Western Blot analysis show an increase in protein synthesis of collagen 3 alpha 1, elastin & fibronectin in murine ON astrocytes after treatment w/ 1 ng/ml TGF-beta 2, 50 ng/ml CCN2/CTGF or 100 ng/ml CCN2/CTGF for 24 h compared to untreated control cells (collagen 3 alpha 1: n = 3, TGF-beta 2 *p = 0.03, 100 ngCTGF **p = 0.009; fibronectin: n = 5, **p = 0.005, 50 ngCTGF **p = 0.006, 100 ng CTGF *p = 0.02; tropoelastin: n = 5, TGF-beta 2 ***p = 0.0004, 50 ngCTGF **p = 0.002, 100 ngCTGF ***p = 0.00001). GAPDH & alpha -tubulin used to normalize protein synthesis & mean value of control cells set at 1. Right panel shows representative Western Blots for all three proteins. Data represented as mean ± SD. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-310202415532092.jpg)
![Immunocytochemistry/ Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - Increasing substratum stiffness causes alterations in murine ON astrocyte reactivity, actin cytoskeleton & CCN2/CTGF level. (A) Filamentous actin labeled by phalloidin (red, upper panel) is increased when murine ON astrocytes were cultured on substrates with higher stiffness (30 kPa, 60 kPa) compared to softer control (10 kPa). Increasing substratum stiffness leads to an enhanced formation of actin stress fibers. Immunoreactivity of CCN2/CTGF (green, middle panel) is markedly increased when murine ON astrocytes were grown on substrates with higher stiffness (30, 60 kPa) compared to softer control (10 kPa). Murine ON astrocytes show an enhanced GFAP protein synthesis (green, lower panel) when cultured on 30 or 60 kPa compared to 10 kPa. Nuclei were stained with Dapi (blue). (B) CCN2/CTGF protein synthesis is significantly increased in murine ON astrocytes grown on 60 kPa compared to 10 kPa (10 kPa: n = 5; 30 kPa: n = 5; 60 kPa: n = 5; *p = 0.04; unpaired two-tailed t-test). (C) Protein synthesis of GFAP (10 kPa: n = 6; 30 kPa: n = 6, **p = 0.005; 60 kPa: n = 4, *p = 0.04; unpaired two-tailed t-test) show an enhanced reactivity of murine ON astrocytes cultured on 30 kPa or 60 kPa compared to 10 kPa control. (D) Vimentin protein synthesis is significantly increased in murine ON astrocytes cultured on 60 kPa compared to 10 kPa (10 kPa: n = 4; 30 kPa: n = 4; 60 kPa: n = 3 ***p = 0.00002). Protein synthesis was normalized to alpha -tubulin & mean value of control (10 kPa) was set at 1. Data represented as mean ± SEM. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-31020241612698.jpg)
![Flow Cytometry: CCR2 Antibody [NBP1-48338] - An intracellular stain was performed on THP-1 cells with CCR2 Antibody NBP1-48338G (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 488.](http://images.novusbio.com/fullsize/CCR2-Antibody-Flow-Cytometry-NBP1-48338-img0004.jpg "Flow Cytometry: CCR2 Antibody [NBP1-48338] - An intracellular stain was performed on THP-1 cells with CCR2 Antibody NBP1-48338G (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 488.")
![Immunocytochemistry/Immunofluorescence: CCR2 Antibody [NBP1-48338] - Analysis of CCR2 in NIH/3T3 cells.](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-48338-img0003.jpg)
![Immunohistochemistry: CCR2 Antibody [NBP1-48338] - Expression patterns of CCL2 and CCR2 in unwounded and wounded corneas of WT and MMP12 KO mice. Immunofluorescence of CCL2 chemokine receptor CCR2 in unwounded and chemically wounded (2-days after injury) WT and Mmp12-/- mouse corneas. Control images represent mouse corneas stained with secondary antibody only and without primary antibody. Nuclei were visualized by staining with DAPI (blue). Scale bars: 50 um. CCR2 staining was visualized in epithelial and stromal layers of unwounded and wounded WT and Mmp12-/- corneas. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-47831-z), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-NBP1-48338-img0007.jpg)
![Flow Cytometry: CCR2 Antibody [NBP1-48338] - An intracellular stain was performed on THP-1 cells with CCR2 Antibody NBP1-48338F (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to FITC.](http://images.novusbio.com/fullsize/CCR2-Antibody-Flow-Cytometry-NBP1-48338-img0006.jpg)
![Flow Cytometry: CCR2 Antibody [NBP1-48338] - The Alexa Fluor 488 conjugate of this antibody was used: Mouse peripheral blood mononuclear cells were unstained (left) or stained (right) with CCR2 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/CCR2-Antibody-Flow-Cytometry-NBP1-48338-img0005.jpg)
![Immunocytochemistry/ Immunofluorescence: CCR2 Antibody - BSA Free [NBP1-48338] - Expression patterns of CCL2 & CCR2 in unwounded & wounded corneas of WT & MMP12 KO mice. (A) Immunofluorescence of CCL2 chemokine & (B) its receptor CCR2 in unwounded & chemically wounded (2-days after injury) WT & Mmp12−/− mouse corneas. Control images represent mouse corneas stained with secondary antibody only & without primary antibody. Nuclei were visualized by staining with DAPI (blue). Scale bars: 50 µm. A magnified image of a wounded WT cornea shows perinuclear expression of CCL2 (orange box). CCL2 staining was visualized in epithelial, stromal, & endothelial layers of wounded WT & Mmp12−/− corneas. CCR2 staining was visualized in epithelial & stromal layers of unwounded & wounded WT & Mmp12−/− corneas. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31399604), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-48338_rabbit-polyclonal-ccr2-antibody-310202415175260.jpg)
![Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Action potentials were evoked with depolarizing current pulses. (A) Neuron from colonic specimen of non-treated patient fired 1 action potential in response to a depolarizing current. (A') Intracellular injection of carboxyfluorescein during recording confirmed Dogiel type I, uniaxonal morphology. (A](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunocytochemistry-Immunofluorescence-NB100-858-img0005.jpg "Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Action potentials were evoked with depolarizing current pulses. (A) Neuron from colonic specimen of non-treated patient fired 1 action potential in response to a depolarizing current. (A') Intracellular injection of carboxyfluorescein during recording confirmed Dogiel type I, uniaxonal morphology. (A")
![Immunohistochemistry-Paraffin: nNOS Antibody [NB100-858] - Staining of paraffin embedded Human Cortex. Steamed antigen retrieval with citrate buffer pH 6, AP-staining. Antibody at 2.5 ug/mL.](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunohistochemistry-Paraffin-NB100-858-img0006.jpg)
![Flow Cytometry: nNOS Antibody [NB100-858] - Flow cytometric analysis of paraformaldehyde fixed Kelly cells (blue line), permeabilized with 0.5% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (1 ug/mL). IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/nNOS-Antibody-Flow-Cytometry-NB100-858-img0003.jpg)
![Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Immunofluorescence analysis of paraformaldehyde fixed HeLa cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL), showing membrane, cytoplasmic and nuclear staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL).](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunocytochemistry-Immunofluorescence-NB100-858-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Wholemount preparations of the myenteric neurons in the distal colon segments following 3 (2a-2d) and 7 (4a-4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 3 (1a-1d) and 7 (3a-3d) days. Myenteric ganglia and neurons labeled with beta-Tubulin Tuj1 (red), nuclei labeled with DAPI (blue) (arrows) can be seen within the ganglion (1b). Smooth muscle cells (asterisks) are also labeled with DAPI (1b). Significant increase in the proportion of nNOS neurons (green) can be seen at both Days 3 and 7 after oxaliplatin treatment. Scale bar = 20 um. Image collected and cropped by CiteAb from the following publication (www.journal.frontiersin.org/article/10.3389/fnins.2013.00030/abstract) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunocytochemistry-Immunofluorescence-NB100-858-img0004.jpg)
![Immunocytochemistry/ Immunofluorescence: nNOS Antibody [NB100-858] - (A) Wholemount preparations of the myenteric neurons in the distal colon segments following 3 (2a–2d) & 7 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 3 (1a–1d) & 7 (3a–3d) days. Myenteric ganglia & neurons labeled with beta -Tubulin Tuj1 (red), nuclei labeled with DAPI (blue) (arrows) can be seen within the ganglion (1b). Smooth muscle cells (asterisks) are also labeled with DAPI (1b). Significant increase in the proportion of NOS neurons (green) can be seen at both Days 3 & 7 after oxaliplatin treatment. Scale bar = 20 μm. (B) Wholemount preparations of the myenteric neurons in the distal colon segments following 14 (2a–2d) & 21 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 14 (1a–1d) & 21 (3a–3d) days. The reduction in total number of neurons & increase in the proportion of NOS neurons was found at both Days 14 & 21 after oxaliplatin treatment. Scale bar = 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23486839), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-858_goat-polyclonal-nnos-antibody-310202416284925.jpg)
![Immunocytochemistry/ Immunofluorescence: nNOS Antibody [NB100-858] - (A) Wholemount preparations of the myenteric neurons in the distal colon segments following 3 (2a–2d) & 7 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 3 (1a–1d) & 7 (3a–3d) days. Myenteric ganglia & neurons labeled with beta -Tubulin Tuj1 (red), nuclei labeled with DAPI (blue) (arrows) can be seen within the ganglion (1b). Smooth muscle cells (asterisks) are also labeled with DAPI (1b). Significant increase in the proportion of NOS neurons (green) can be seen at both Days 3 & 7 after oxaliplatin treatment. Scale bar = 20 μm. (B) Wholemount preparations of the myenteric neurons in the distal colon segments following 14 (2a–2d) & 21 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 14 (1a–1d) & 21 (3a–3d) days. The reduction in total number of neurons & increase in the proportion of NOS neurons was found at both Days 14 & 21 after oxaliplatin treatment. Scale bar = 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23486839), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-858_goat-polyclonal-nnos-antibody-310202416284920.jpg)
![Western Blot: CD44 Antibody [NBP1-31488] - Untreated (-) and treated (+) MDA-MB-231 whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with CD44 antibody. The observed M.W. is different from the predicted size. It is possibly due to post-translational modifications.](http://images.novusbio.com/fullsize/CD44-Antibody-Western-Blot-NBP1-31488-img0031.jpg "<b>Biological Strategies Validation. </b>Western Blot: CD44 Antibody [NBP1-31488] - Untreated (-) and treated (+) MDA-MB-231 whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with CD44 antibody. The observed M.W. is different from the predicted size. It is possibly due to post-translational modifications.")
![<b>Biological Strategies Validation. </b>Western Blot: CD44 Antibody [NBP1-31488] - Untreated (-) and treated (+) HeLa whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with CD44 antibody. The observed M.W. is different from the predicted size. It is possibly due to post-translational modifications.](http://images.novusbio.com/fullsize/CD44-Antibody-Western-Blot-NBP1-31488-img0033.jpg)
![Immunocytochemistry/Immunofluorescence: CD44 Antibody [NBP1-31488] - Analysis of methanol-fixed HeLa, using CD44 antibody (Green) at 1:500 dilution. Alpha-tubulin filaments were labeled with an alpha Tubulin antibody (Red) at 1:2000.](http://images.novusbio.com/fullsize/CD44-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-31488-img0016.jpg)
![Immunohistochemistry-Paraffin: CD44 Antibody [NBP1-31488] - Human cervical carcinoma. CD44 stained by CD44 antibody diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/CD44-Antibody-Immunohistochemistry-Paraffin-NBP1-31488-img0036.jpg)
![Immunohistochemistry-Paraffin: CD44 Antibody [NBP1-31488] - Human endometrial carcinoma. CD44 antibody diluted at 1:500. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min.](http://images.novusbio.com/fullsize/CD44-Antibody-Immunohistochemistry-Paraffin-NBP1-31488-img0026.jpg)
![Immunohistochemistry-Paraffin: CD44 Antibody [NBP1-31488] - Human pancreatic tumor, using CD44 antibody at 1:100 dilution. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min.](http://images.novusbio.com/fullsize/CD44-Antibody-Immunohistochemistry-Paraffin-NBP1-31488-img0035.jpg)
![Immunocytochemistry/ Immunofluorescence: CD44 Antibody [NBP1-31488] - CD44 antibody detects CD44 protein at cell membrane by immunofluorescent analysis.Sample: A431 cells were fixed in ice-cold MeOH for 5 min.Green: CD44 stained by CD44 antibody (NBP1-31488) diluted at 1:500.Blue: Fluoroshield with DAPI .](http://images.novusbio.com/fullsize/nbp1-31488_rabbit-polyclonal-cd44-antibody-91020242091445.jpg)
![Western Blot: CD44 Antibody [NBP1-31488] - Untreated (-) and treated (+) HeLa whole cell extracts (30 ug) were separated by 10% SDS-PAGE, and the membrane was blotted with CD44 antibody (NBP1-31488) diluted at 1:45000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced.](http://images.novusbio.com/fullsize/nbp1-31488_rabbit-polyclonal-cd44-antibody-910202420104431.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: CD44 Antibody [NBP1-31488] - Non-transfected (–) and transfected (+) Wild-type (WT) and G CD44 knockout (KO) HeLa cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with CD44 antibody diluted at 1:7000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp1-31488_rabbit-polyclonal-cd44-antibody-1610202419405756.jpg)
![<b>Orthogonal Strategies Validation. </b>Western Blot: CD44 Antibody [NBP1-31488] - Various whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with CD44 antibody diluted at 1:5000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody. Corresponding RNA expression data for the same cell lines are based on Human Protein Atlas program.](http://images.novusbio.com/fullsize/nbp1-31488_rabbit-polyclonal-cd44-antibody-1610202419414564.jpg)
![Immunohistochemistry-Paraffin: CD163 Antibody (10D6) [NB110-59935] - Formalin fixed paraffin embedded human tonsil stained with CD163 antibody (NB110-59935).](http://images.novusbio.com/fullsize/CD163-Antibody-10D6-Immunohistochemistry-Paraffin-NB110-59935-img0003.jpg "Immunohistochemistry-Paraffin: CD163 Antibody (10D6) [NB110-59935] - Formalin fixed paraffin embedded human tonsil stained with CD163 antibody (NB110-59935).")
![Immunohistochemistry-Paraffin: CD163 Antibody (10D6) [NB110-59935] - Human tonsil.](http://images.novusbio.com/fullsize/CD163-Antibody-10D6-Immunohistochemistry-Paraffin-NB110-59935-img0001.jpg)
![Immunohistochemistry-Paraffin: CD163 Antibody (10D6) [NB110-59935] - Human lymph node stained with CD163 antibody showing cytoplasmic staining in non-germinal center cells. Image from verified customer review.](http://images.novusbio.com/fullsize/CD163-Antibody-10D6-Immunohistochemistry-Paraffin-NB110-59935-img0002.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Staining of human peripheral blood lymphocytes with anti-human CD45 antibody (MEM-28) Alexa Fluor 700.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0021.jpg "Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Staining of human peripheral blood lymphocytes with anti-human CD45 antibody (MEM-28) Alexa Fluor 700.")
![Immunocytochemistry/Immunofluorescence: CD45 Antibody (MEM-28) [NB500-319] - staining of human peripheral blood mononuclear cell using anti-human CD45 antibody (MEM-28) (green). DNA visualized by DAPI (blue).](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Immunocytochemistry-NB500-319-img0001.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Staining of human peripheral blood cells with anti-human CD45 antibody (MEM-28) PE-CyTM5.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0018.jpg)
![Immunohistochemistry-Paraffin: CD45 Antibody (MEM-28) [NB500-319] - Staining of human small intestine (paraffin-embedded sections) with CD45 antibody (MEM-28), 10 ug/ml.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Immunohistochemistry-Paraffin-NB500-319-img0022.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Surface staining of human peripheral blood cells with anti-human CD45 antibody (MEM-28) PerCP-CyTM5.5.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0007.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Surface staining of human peripheral blood cells with anti-human CD45 antibody (MEM-28) purified, GAM-APC.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0008.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Surface staining of human peripheral blood cells with anti-human CD45 antibody (MEM-28) APC-CyTM7.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0010.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Staining of human peripheral blood cells with anti-human CD45 antibody (MEM-28) Pacific BlueTM.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0016.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Staining of human peripheral blood cells with anti-human CD45 antibody (MEM-28) PE.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0017.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Staining of human peripheral blood cells with anti-human CD45 antibody (MEM-28) PE-CyTM7.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0019.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Staining of human peripheral blood cells with anti-human CD45 antibody (MEM-28) PE-DyLight (R) 594.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0020.jpg)
![Western Blot: p38 [p Thr180, p Tyr182] Antibody [NB500-138] - Hela cell lysates that had been treated with UV or untreated (Control) showing specific immunolabeling of the -39 kDa p38 MAPK protein phosphorylated at Thr180/Tyr182.](http://images.novusbio.com/fullsize/p38-[p-Thr180--p-Tyr182]-Antibody-Western-Blot-NB500-138-img0005.jpg "Western Blot: p38 [p Thr180, p Tyr182] Antibody [NB500-138] - Hela cell lysates that had been treated with UV or untreated (Control) showing specific immunolabeling of the -39 kDa p38 MAPK protein phosphorylated at Thr180/Tyr182.")
![Immunohistochemistry-Paraffin: p38 [p Thr180, p Tyr182] Antibody [NB500-138] - Immunostaining of human breast cancer tissue showing p38 when phosphorylated at Thr180/Tyr182 in red.](http://images.novusbio.com/fullsize/p38-[p-Thr180-p-Tyr182]-Antibody-Immunohistochemistry-Paraffin-NB500-138-img0002.jpg)
![Western Blot: p38 [p Thr180, p Tyr182] Antibody [NB500-138] - Western blot of HeLa cell lysates that had been treated with UV or untreated (Control) showing specific immunolabeling of the ~39k p38 MAPK protein phosphorylated at Thr180/Tyr182.](http://images.novusbio.com/fullsize/p38-[p-Thr180-p-Tyr182]-Antibody-Western-Blot-NB500-138-img0001.jpg)
![Western Blot: p38 alpha [p Thr180, p Tyr182] Antibody [NB500-138] - RIP2 is not essential for MAPK pathways in the early ontogenesis. (A) Immunoblot analysis of phospho-p44/42 MAPK, p44/42 MAPK, & p38 MAPK in larvae homogenate from WT & NOD1-1IS−/− zebrafish at 7 days post-fertilization (dpf). (B) Immunoblot analysis of phospho-p44/42 MAPK, p44/42 MAPK, & p38 MAPK in larvae homogenate from WT & RIP2−/− zebrafish at 7 dpf. (C) Immunoblot analysis of Atg5, p62, & LC3b in larvae homogenate from WT & NOD1-1IS−/− zebrafish at 7 dpf. (D) Immunoblot analysis of Atg5, p62, & LC3b in larvae homogenate from WT & RIP2−/− zebrafish at 7 dpf. Western blotting results were quantified using Quantity One software. Data represent the average of two independent experiments. *p < 0.05, **p < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29692779), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-138_rabbit-polyclonal-p38-alpha-p-thr180-p-tyr182-antibody-31020241534371.jpg)
![Western Blot: TGF-beta 1 Antibody [NBP1-80289] - Sample Tissue: Human Fetal Heart. Antibody Dilution: 1.0ug/ml](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-Western-Blot-NBP1-80289-img0013.jpg "Western Blot: TGF-beta 1 Antibody [NBP1-80289] - Sample Tissue: Human Fetal Heart. Antibody Dilution: 1.0ug/ml")
![Immunocytochemistry/Immunofluorescence: TGF-beta 1 Antibody [NBP1-80289] - Mouse kidney (red fluorescence). Nuclei were stained with DAPI (blue fluorescence). Working dilutions: 5-10 ug/ml](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-80289-img0008.jpg)
![Immunohistochemistry-Paraffin: TGF-beta 1 Antibody [NBP1-80289] - Human Appendix FFPE tissue section stained with TGF-beta 1 antibody. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-Immunohistochemistry-Paraffin-NBP1-80289-img0011.jpg)
![Western Blot: TGF-beta 1 Antibody [NBP1-80289] - Antibody Titration: 0.2-1 ug/ml or 1:5000 to 1:1000 Dilution. SP2/0 cell lysate.](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-Western-Blot-NBP1-80289-img0010.jpg)
![Western Blot: TGF-beta 1 Antibody [NBP1-80289] - Sample Tissue: Mouse Spleen. Antibody Dilution: 1ug/ml](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-Western-Blot-NBP1-80289-img0012.jpg)
![Western Blot: TGF-beta 1 Antibody [NBP1-80289] - Sample Tissue: Mouse Pancreas. Antibody Dilution: 1ug/ml](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-Western-Blot-NBP1-80289-img0014.jpg)
![Immunohistochemistry-Paraffin: TGF-beta 1 Antibody [NBP1-80289] - Human Spleen Tissue, 5 ug/ml.](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-Immunohistochemistry-Paraffin-NBP1-80289-img0007.jpg)
![Immunohistochemistry-Paraffin: TGF-beta 1 Antibody [NBP1-80289] - Human prostate cancer tissue was detected using RP/AEC red color stain. Working dilutions: 5-10 ug/ml.](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-Immunohistochemistry-Paraffin-NBP1-80289-img0009.jpg)
![Imaging Mass Cytometry: TGF-beta 1 Antibody [NBP1-80289] - Human bone marrow FFPE tissue sections. DNA in blue, TGF-beta 1 antibody staining in white. IMC image submitted by a verified customer review.](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-Imaging-Mass-Cytometry-NBP1-80289-img0015.jpg)
![Immunocytochemistry/Immunofluorescence: Rabbit Polyclonal TGF-beta 1 Antibody [NBP1-80289] - Mice hepatocytes stained with TGF-beta 1 Antibody. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nbp1-80289_rabbit-polyclonal-tgf-beta-1-antibody-immunocytochemistry-immunofluorescence-25112024112535..png)
